Sequence: GRKKRRQRRR
| Experiment Id | EXP002420 |
|---|---|
| Paper | Effect of HIV-1 TAT Peptide Fusion on 5′ mRNA Cap Analogs Cell Membrane Permeability and Translation |
| Peptide | HIV-1 TAT |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 5–50 µM conjugate |
| Rna Concentration | 5–50 µM conjugate |
| Mixing Ratio | 1:1 covalent conjugate |
| Formulation Format | CPP–nucleotide conjugate |
| Formulation Components | TAT peptide + m7GpppG cap analog |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | MCF-7 breast cancer cells |
| Animal Model | |
| Administration Route | cell incubation |
| Output Type | translation inhibition |
| Output Value | Up to ~30% inhibition of cap-dependent translation |
| Output Units | |
| Output Notes | Cytosolic distribution in ~85% cells; partial endosomal sequestration observed |
| Toxicity Notes | No cytotoxicity up to 50 µM |
| Curation Notes |